Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes.
Endocannabinoids exert their biological effects via interaction with G-protein coupled cannabinoid receptors CB1 and CB2. Polymorphisms in the CNR1 gene (encoding CB1 receptor) were previously found to be associated with dyslipidemia and cardiovascular diseases. We investigated a role of the polymorphism in CNR1 gene in type 2 diabetes and its complications. The study involved 667 T2DM patients and 450 healthy individuals. All subjects were genotyped for G1359A polymorphism by PCR-RFLP procedure. Genotype frequencies did not differ significantly between patients and controls. The statistically significant differences were seen between T2DM patients with diabetic nephropathy (DN) and those without it (OR for risk allele 2.84, 95% CI 2.04-3.94, p<0.0001). There were also differences between patients with diabetic retinopathy (DR) and those without DR (OR for risk allele 1.81, 95% CI 1.30-2.53, p=0.0005). No differences were observed in diabetic neuropathy. The A allele was more frequent in patients with coexisting cardiovascular disease (CVD) compared to patients without CVD (p=0.0044). The novel finding of our study is the association of the G1359A polymorphism with diabetic nephropathy and diabetic retinopathy in patients with T2DM. This polymorphism was also associated with cardiovascular disease in the patient group.
Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, 20-954 Lublin, Poland. Electronic address: monika.buraczynska@umlub.pl.
Monika
M
Buraczynska
Department of Cardiology, Medical University of Lublin, 20-954 Lublin, Poland.
Piotr
P
Wacinski
Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, 20-954 Lublin, Poland.
Pawel
P
Zukowski
Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, 20-954 Lublin, Poland.
Michal
M
Dragan
Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, 20-954 Lublin, Poland.
Andrzej
A
Ksiazek
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000453:epidemiology / Q000235:genetics*; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000235:genetics*; D003928:Diabetic Nephropathies / Q000453:epidemiology / Q000235:genetics; D003930:Diabetic Retinopathy / Q000453:epidemiology / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics*
C571130:CNR1 protein, human; D043884:Receptor, Cannabinoid, CB1
Diabetic nephropathy; Diabetic retinopathy; Gene polymorphism; Risk allele; Type 2 diabetes